Partner Headlines - BMRN

  1. BIOMARIN PHARMA

    IBD
  2. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  3. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  4. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  5. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  6. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  7. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  8. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  9. BIOMARIN PHARMA

    IBD
  10. State Of The Union Lights Up Biotech

    Benzinga
  11. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  12. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  13. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  14. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  15. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  16. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  17. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  18. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  19. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  20. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  21. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  22. BioMarin buying Prosensa

    IBD
  23. Trio Of Major Deals Disclosed

    IBD
  24. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  25. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  26. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  27. Benzinga's Volume Movers

    Benzinga
  28. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  29. Stocks Hitting 52-Week Highs

    Benzinga
  30. Morning Market Movers

    Benzinga
  31. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  32. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  33. Benzinga's Top #PreMarket Gainers

    Benzinga
  34. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  35. Stocks Hitting 52-Week Highs

    Benzinga
  36. Benzinga's Top Upgrades

    Benzinga
  37. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  38. BioMarin Weathers The Storm

    Benzinga
  39. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  40. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  41. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  42. Benzinga's Top Upgrades

    Benzinga
  43. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  44. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  45. Top Trending Tickers On StockTwits For February 18

    Benzinga
  46. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  47. You Can No Longer Ignore Biotech

    GuruFocus
  48. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  49. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  50. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  51. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  52. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  53. Benzinga's Top #PreMarket Gainers

    Benzinga
  54. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  55. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  56. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  57. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  58. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  59. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  60. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  61. Roche

    IBD
  62. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  63. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  64. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  65. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  66. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  67. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  68. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  69. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  70. Benzinga's Volume Movers

    Benzinga
  71. Benzinga's Top Pre-Market Gainers

    Benzinga
  72. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  73. Benzinga's Top Pre-Market Gainers

    Benzinga
  74. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  75. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  76. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  77. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  78. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  79. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  80. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  81. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  82. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  83. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  84. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  85. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  86. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  87. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  88. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  89. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  90. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  91. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  92. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  93. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  94. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  95. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  96. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  97. BioMarin soars on drug data

    IBD
  98. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
  99. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical ...

    Benzinga
  100. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga
Trading Center